- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Siemens debuts tissue harmonic imaging
Siemens Ultrasound of Issaquah, WA, has become the latest ultrasound vendor to add tissue harmonic imaging capabilities to its product line. The firm's version, called Ensemble Tissue Harmonic Imaging, will be offered on its premium Sonoline Elegra
Siemens Ultrasound of Issaquah, WA, has become the latest ultrasound vendor to add tissue harmonic imaging capabilities to its product line. The firm's version, called Ensemble Tissue Harmonic Imaging, will be offered on its premium Sonoline Elegra ultrasound scanners.
The new release allows Elegra users to isolate harmonic signal data without the use of contrast agents, according to the firm. Ensemble supports high-frequency imaging and can provide demonstration of breast lesions and superficial images. The system also shows promise in scanning difficult-to-image patients.
Ensemble eliminates the impact of signal artifacts common during high-frequency scanning with its pulse-inversion technology, which isolates harmonic imaging signals, according to Siemens. Combining the harmonic imaging signals with fundamental signal data allows Elegra to yield improvements in tissue contrast and spatial resolution in nearly all radiological applications, the company believes.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
